Meilin Diaz-Paez, APRN, MSN

Elisa Krill-Jackson, MD, is a board- certified hematologist and oncologist at Sylvester Comprehensive Cancer Center. At Sylvester, Dr Krill-Jackson works as part of a multidisciplinary team of cancer experts and researchers. Dr Krill-Jackson specializes in breast cancer and gynecologic cancers, as well as hematology. Dr Krill-Jackson believes in educating her patients about their conditions so they can work together as a team in fighting their cancer. While using the most state of the art treatments and clinical trials, she believes in treating the whole patient with compassion and supporting her patients' physical and emotional needs. She earned her medical degree from University of Michigan Medical School.

Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, is the only NCI-designated cancer center in South Florida, offering specialized care in oncology and a wide range of other medical specialties. The center is dedicated to providing world-class patient care through innovative treatments, research, and collaborative approaches among expert teams. In addition to cancer care, Sylvester Comprehensive Cancer Center features comprehensive services across various fields, including ophthalmology, neurology, and bariatrics, ensuring patients receive integrated and personalized medical attention. With a commitment to high-quality care, the facility emphasizes patient-centered approaches and the latest advances in medical research for effective treatment outcomes. Generated from the website

Dr Jimenez Jimenez, who joined the Division of Transplantation and Cell Therapy in 2016, leads Sylvester's Mismatched Allogeneic Transplant Program. His clinical and research work is dedicated to improving access to Hematopoietic Cell Transplantation (HCT) for ethnically diverse patients who lack suitable donors. A national leader in mismatched HCT, Dr Jimenez chairs multiple trials and played a key role in establishing Sylvester's program. He also focuses on strategies to reduce relapse risk in patients with acute leukemias and myeloid neoplasms post-transplant.